Aim. To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register. Material and methods.The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 — 2770. Patients diagnosed with COVID-19 receiving in- and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two nonoverlapping branches (in- and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months. Results. According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3- and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure. Conclusion. According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period.
The potential impact on cardiovascular morbidity and mortality have become one of the most important issues of the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 may be associated with more frequent development of acute cardiovascular complications, while patients with established cardiovascular diseases are characterized by a higher risk of severe infection and adverse in-hospital outcomes. Due to the spread scale of the pandemic, understanding the long-term cardiovascular consequences of COVID-19 is of no less importance. Inability to extrapolate available international data to the Russian population has led to the initiation of a national multicenter study (registry) of patients recovered from COVID-19 and with concomitant involvement of the cardiovascular system or with baseline severe cardiovascular diseases. The article presents its rationale, design and implications of the results for clinical practice.
COVID-19 is a severe infection with high mortality. The concept of the disease has been shaped to a greater extent on the basis of large registers from the USA, Spain, Italy, and China. However, there is no information on the disease characteristics in Caucasian patients.Therefore, we created an international register with the estimated capacity of 5,000 patients — Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (AKTIV SARS-CoV-2), which brought together professionals from the Russian Federation, Republic of Armenia, Republic of Kazakhstan, and Kyrgyz Republic. The article presents the first analysis of the register involving 1,003 patients. It was shown that the most significant difference of the Caucasian population was the higher effect of multimorbidity on the mortality risk vs other registers. More pronounced effect on mortality of such diseases as diabetes, obesity, hypertension, chronic kidney disease, and age over 60 years was also revealed.
Цель. В последние годы интерес к проблеме дисфункции эндотелия значи-тельно возрос. Доказано, что микроциркуляторные нарушения играют основ-ную роль в возникновении и прогрессировании поражения органов-мишеней при гипертонической болезни (ГБ). Именно микроциркуляторное русло можно считать одной из мишеней ГБ. Современные гипотензивные препараты помимо нормализации артериального давления (АД) должны обеспечивать профилактику поражения органов-мишеней. В нашем исследовании изуча-лось влияние терапии фиксированной комбинацией периндоприла А и амло-дипина (Престанс ® , "Лаборатории Сервье", Франция) на структурно-функцио-нальные параметры сердца и сосудов. INFLUENCE OF THE COMBINATION DRUG PRESTANS (PERINDOPRIL A, AMLODIPINE) ON MORPHO-FUNCTIONAL PARAMETERS OF ARTERIAL BED IN ESSENTIAL HYPERTENSIONDanilogorskaya Yu. A., Zheleznykh E. A., Privalova E. V., Shchendrygina A. A., Belenkov Yu. N., Ilgisonis I. S., Tishman M. I. Aim.Recently, the problem of endothelial dysfunction is in high interest. It was proved that microcirculatory disorders play main role in development and progression of target organ damage in essential arterial hypertension (EAH). Microcirculatory bed itself should be the target of EAH. Modern antihypertension drugs, despite of normalization of blood pressure (BP), should fulfill the prevention of target organ damage. In our study, the influence was evaluated, of treatment with the fixed combination of perindopril A and amlodipine (Prestans ® , "Les Laboratoires Servier", France) on structural and functional parameters of the heart and vessels. Material and methods. In the study, 30 patients with grade II-III EAH included, mean age 54,12±9,15 y. o., duration of 6 (4;21) years. For the assessment of endothelial function and structural and functional condition of capillary net of a finger skin, photopletysmography were applied and videocapillroscopy, respectively. Results. Therapy with Prestans ® led to improvement of functioning of the middle sized vessels and microcirculatory vessels (MC) (increase of occlusion index on MC level from 1,5 to 1,8, p<0,006); on the large vessels level led to phase shift from 6,0 to 10,3 (р<0,00005
Hydroxychloroquine (HCH) is included in guidelines for treatment of novel coronavirus infection (COVID-19). Data on increased risk of cardiovascular complications when using it have been published. Aim. To evaluate the safety and tolerability of HCH and azithromycine (AZM) combination for the treatment of the patients with COVID-19 in recommended by Russian Ministry of Health doses in real practice.Methods. 132 patients (62 men and 70 women of average age 59.2 ± 9.3 years), 59% of whom had cardiovascular comorbidities, were included in prospective сohort study. 112 patients took HCH + AZM (group 1) and 20 patients took other medications without potential cardiotoxicity (group 2). At the admission to the hospital and after 5–7 days of the treatment corrected QT interval was calculated, new rhythm and conduction disorders, other side effects and hospital mortality have been registering. Relative risk (RR) and 95% confidence interval (CI) were calculated. Results. Elongation of corrected QT-interval within the normal range was registered in 22.3% of patients in group 1 and in 15% — in group 2. An increase in the QT length to the upper limit of the norm (480 msec) was observed in 1.8% of patients in group 1. There were no statistically significant differences between the groups in the number of patients with prolonged QT interval (RR = 1.488, 95% CI: 0.496–4.466, р = 0.478). The occurrence of new arrhythmias, conduction disturbances and allergic reactions was not recorded. Tolerability of combination HCH + AZM was satisfactory in the majority of patients. The hospital mortality in group 1 was 1.8%, in group 2 — 5% without statistically significant difference (p = 0.374). Conclusion. A combination of HCL + AZM according to the scheme recommended by the Ministry of Health of the Russian Federation for the treatment of the patients with COVID-19 and cardiovascular comorbidity in inpatient conditions is safe.
Цель. Разработка модели расчета риска развития венозного тромбоза с учетом наличия известных факторов риска, сопутствующей патологии и врожденных тромбофилий. Материал и методы. В ходе работы с 2015 по 2017гг было обследовано 79 пациентов с венозными тромбозами (36 мужчин и 43 женщины, средний возраст-56,76±15,57). Группу контроля составили 83 пациента стационара и здоровых добровольцев без тромбоза в настоящий момент и в анамнезе (35 мужчин и 48 женщин, средний возраст-43,95±18,136). Всем лицам, включенным в исследование, проводился анализ на наличие мутаций G1691A в гене фактора V, G20210A в гене протромбина, полиморфизм C677T в гене 5,10-метилентетрагидрофолатредуктазы, а также полиморфизм в гене SERPINE1 ингибитора активатора плазминогена-1. Для выявления мутаций применялась полимеразная цепная реакция методом Real time. Для создания модели расчета риска был проведен линейный регрессионный анализ. Результаты. Нами была разработана модель расчета риска венозных тромбозов. Полученная формула показала высокую прогностическую точность (площадь под ROC-кривой-95,9%). Для пациентов, у которых нет данных о наличии перечисленных мутаций, была разработана короткая версия модели расчета риска (площадь под ROC-кривой-94,6%). Заключение. Нами была разработана модель расчета риска с учетом наличия известных факторов, врожденных тромбофилий и сопутствующей патологии. Следует обсуждать необходимость тромбопрофилактики при индивидуальном риске более 0,45, что соответствует высокому риску развития венозных тромбозов. Пациентам, которым раннее не проводилась диагностика тромбофилий и находящихся в средней группе риска венозного тромбоза, по данным укороченной версии модели рекомендуется проводить скрининг на врожденные тромбофилии для уточнения риска.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.